Citius Pharmaceuticals, Inc. (CTXR) Stock Price & How to Invest

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company that develops and, more recently, commercializes specialty products. Its lead asset is LYMPHIR (denileukin diftitox-cxdl), a targeted immunotherapy approved by the FDA for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have had at least one prior systemic therapy. LYMPHIR is being commercialized largely through Citius Oncology (Nasdaq: CTOR), a separately listed subsidiary in which Citius Pharmaceuticals holds a majority stake (a stake that has declined over time as the subsidiary raised financing). Beyond LYMPHIR, the company's pipeline includes Mino-Lok, an antibiotic catheter-lock solution that met the primary and secondary endpoints of its Phase 3 trial, and CITI-002 (Halo-Lido), a topical treatment for hemorrhoids.

The company transitioned from a pure development-stage biotech to an early commercial one when LYMPHIR sales began in late 2025, generating a few million dollars of revenue in the following quarters at high gross margins as Citius Oncology built payer coverage and formulary access. The larger story for shareholders, though, is financial fragility. Citius reported only about $4.6 million of cash as of March 31, 2026, executed a 1-for-25 reverse stock split in November 2024 to maintain its Nasdaq minimum-bid-price compliance, and has repeatedly raised capital through equity and debt offerings that dilute existing holders. As a result, the investment case is less about traditional earnings and more about whether LYMPHIR's commercial ramp and pipeline progress can outpace the company's cash needs before further dilution or financing pressure erodes value.

The dominant risks are financial. Citius reported only about $4.6 million of cash as of March 31, 2026, so it likely needs additional financing, and its history of equity and debt raises means existing shareholders face ongoing dilution. The company executed a 1-for-25 reverse stock split in late 2024 to maintain Nasdaq compliance, and continued listing depends on meeting exchange requirements. As a small, early-commercial biopharma, it is not consistently profitable, so traditional valuation metrics like P/E carry little meaning. Commercial risk is real: LYMPHIR targets a niche relapsed or refractory CTCL population, and the revenue ramp is still early and unproven. Pipeline candidates such as Mino-Lok and Halo-Lido face regulatory and funding hurdles before they can contribute. The subsidiary structure (LYMPHIR inside Citius Oncology, CTOR) also means CTXR shareholders own the lead asset indirectly. This is a speculative stock where the range of outcomes, including significant loss, is wide.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Citius Pharmaceuticals, Inc.'s investor relations page or your broker.

• Profitability: Not consistently profitable; an early-commercial biopharma, so no meaningful P/E
• Cash position: ~$4.6 million reported as of March 31, 2026 (approximate; a key constraint)
• LYMPHIR revenue: A few million dollars since the late-2025 launch (about $5.6 million net for the first half of fiscal 2026, at roughly 80% gross margins; approximate)
• Share structure: 1-for-25 reverse stock split effected November 2024 to maintain Nasdaq listing; ongoing dilution from financings
• Subsidiary: Majority stake in Citius Oncology (Nasdaq: CTOR), which holds and commercializes LYMPHIR
• Market cap: Small-cap / micro-cap, so the shares can be volatile and thinly traded

Figures are approximate and tied to the asOf date; verify live numbers before acting. For a small, early-commercial biopharma like Citius, standard valuation multiples such as P/E are not useful because the company is not consistently profitable. What matters far more is cash runway, the pace of the LYMPHIR revenue ramp, pipeline progress, and how much shareholder dilution future financing requires. The reverse split and low cash balance are central to the risk picture and should be weighed carefully alongside any commercial optimism.

There are three common ways to get CTXR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CTXR sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where CTXR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Citius Pharmaceuticals is a speculative small-cap biopharma built around its newly launched LYMPHIR immunotherapy and a majority stake in Citius Oncology. The upside is early commercial traction, but the stock carries steep risks: very low cash, a history of dilution, a prior reverse split, and a still-unproven revenue ramp.